A 72 year old man developed acute myeloblastic leukaemia two years after he had been treated with local curative therapy and chemotherapy for a solitary plasma cytoma of the ilium.
Introduction
Localized plasmacytomas constitute less than 10% of malignant plasma cell dyscrasias. Some plasmacytomas develop singly and remain solitary either in bone marrow (solitary myeloma) or in soft tissues (extramedullary plasmacytomas). The association of multiple myeloma and acute non-lymphocytic leukaemia is well documented (Bersagel, 1982; Drivsholm et al., 1985) . The occurrence of acute myeloid leukaemia in a patient with an untreated primary colonic plasmacytoma has also been reported (Ohmori et al., 1984) . This is the first report CLINICAL REPORTS was no evidence of dissemination of plasmacytoma to multiple myeloma at post-mortem.
Discussion
The prognosis of patients presenting with localized plasmacytomas is much better than that of patients with disseminated plasma cell dyscrasias such as multiple myeloma and plasma cell leukaemia (Woodruffet al., 1979; Wollersheim et al., 1984) . Even cases of localized plasmacytoma with subsequent dissemination survive longer than those treated for overt multiple myeloma (Alexanian, 1980) . Such data suggest that localized plasmacytoma is a disorder which is related to but distinct from multiple myeloma. There is as yet no reliable means of prospectively distinguishing patients with occult multiple myeloma and those with truly solitary plasmacytoma, and it is recommended that all patients with apparent solitary plasmacytoma must receive curative local therapy with surgery and high doses of radiation therapy (> 5,000 cGy) (Woodruff et al., 1979; Bataille et al., 1981) . In addition it has been suggested that patients with localized plasmacytomas who have evidence of sub-clinical dissemination with large amounts ofmonoclonal protein in serum or urine might benefit from early adjuvant chemotherapy (Bataille, 1982) . However, there are no clinical trials to support this recommendation.
A major disadvantage oflong-term chemotherapy is the possible occurrence of acute leukaemia. An increasing number of cases with both multiple myeloma and acute leukaemia have been published (Kyle et al., 1970; Rosner & Gurnwald, 1984) . The incidence of acute leukaemia in multiple myeloma has been reported to be between 100 and 230 times greater than the predicted incidence in normal individuals (Bergsagel, 1982) . This increased incidence has been attributed to the use ofcytostatic agents especially alkylating agents though a causal relationship is yet to be documented.
In our patient, the large amount of urinary Bence Jones protein at presentation suggested a high tumour mass and curative local therapy was supplemented with adjuvant chemotherapy. However there was no evidence of dissemination to multiple myeloma and this was further supported by the return of urinary protein levels to near normal after treatment. The development of acute myeloid leukaemia in our patient suggests that the use of alkylating agents in the treatment of solitary plasmacytomas should only be considered when there is evidence of overt dissemination to multiple myeloma. The high risk of acute leukaemia associated with the use of alkylating agents has to be balanced against the relatively good prognosis of solitary plasmacytomas. However, if early adjuvant chemotherapy is to be used in the treatment of those patients with localized plasmacytomas and evidence of sub-clinical dissemination then regimes including methyl prednisolone, dexamethasone, vincristine and adriamycin which have not been implicated in the development of acute leukaemia should be considered.
